Michel Ducreux

Citado por

	Total	Desde 2016
Citas	55501	25725
Índice h	109	66
Índice i10	390	259

5000

2500

1250

3750

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021148 214 296 489 613 778 912 1022 1315 1428 1853 1935 2231 2452 2832 2942 3368 3697 3839 4015 4124 4174 4922 4576

Acceso público

Ver todo

7 artículos

2 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Sabourin jcProfesseur, anatomie pathologique, CHU de RouenDirección de correo verificada de chu-rouen.fr
Pierre Laurent-PuigUnisveristé Paris DescartesDirección de correo verificada de parisdescartes.fr
BennounaProfesseur d'oncologie médicaleDirección de correo verificada de univ-nantes.fr
julien Taiebprofessor of medecine Hopital Europeen Georges Pompidou, Université de Paris (Paris-DescartesDirección de correo verificada de egp.aphp.fr
jean-luc RaoulDirección de correo verificada de ico.unicancer.fr
Antoine HollebecqueConsultant, Gustave Roussy Cancer Campus, VillejuifDirección de correo verificada de gustaveroussy.fr
Joël GuigayProfesseur de médecinDirección de correo verificada de nice.unicancer.fr
Timothy PriceThe Queen Elizabeth Hospital and School of Medicine University of AdelaideDirección de correo verificada de adelaide.edu.au
Pascal HammelDirección de correo verificada de aphp.fr
Florian LordickUniversity Cancer Center LeipzigDirección de correo verificada de medizin.uni-leipzig.de
Cervantes AProfessor of Medicine. University of ValenciaDirección de correo verificada de uv.es
Philippe RuszniewskiPROFESSOR OF GASTROENTEROLOGYDirección de correo verificada de aphp.fr
nathalie LassauProfessor at Gustave Roussy University Paris SaclayDirección de correo verificada de gustaveroussy.fr
Lambros TselikasInterventional Radiology - Gustave Roussy Cancer InstituteDirección de correo verificada de gustaveroussy.fr
Jean-Charles SoriaGustave Roussy and University Paris SaclayDirección de correo verificada de gustaveroussy.fr
Stefan MichielsHead Office Biostatistics & Epidemiology, Gustave Roussy; Head Oncostat, Inserm Univ. Paris SaclayDirección de correo verificada de gustaveroussy.fr
David CunninghamThe Royal Marsden NHS Foundation TrustDirección de correo verificada de rmh.nhs.uk
Angelo PaciGustave RoussyDirección de correo verificada de gustaveroussy.fr
John NeoptolemosUniversity of HeidelbergDirección de correo verificada de med.uni-heidelberg.de
Laurence ZitvogelInstitut Gustave Roussy, Université de Paris Saclay, INSERMDirección de correo verificada de igr.fr

Michel Ducreux

Université Paris-Saclay, Gustave Roussy

Dirección de correo verificada de gustaveroussy.fr

Oncology Gastro-Intestinal Tumours Neuroendocrine Tumours


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, ... New England journal of medicine 364 (19), 1817-1825, 2011	5686	2011
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer A Lievre, JB Bachet, D Le Corre, V Boige, B Landi, JF Emile, JF Côté, ... Cancer research 66 (8), 3992-3995, 2006	2509	2006
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016	2050	2016
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 JP Gérard, T Conroy, F Bonnetain, O Bouché, O Chapet, ... Journal of clinical oncology 24 (28), 4620-4625, 2006	1895	2006
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014	1842	2014
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008	1796	2008
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T Andre, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005	1131	2005
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … M Peeters, T Jay Price JOURNAL OF CLINICAL ONCOLOGY, 2010	1082	2010
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, TY Kim, M Kudo, V Breder, ... New England Journal of Medicine 382 (20), 1894-1905, 2020	978	2020
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Ducreux, AS Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, ... Annals of Oncology 26, v56-v68, 2015	849	2015
Immunogenic death of colon cancer cells treated with oxaliplatin A Tesniere, F Schlemmer, V Boige, O Kepp, I Martins, F Ghiringhelli, ... Oncogene 29 (4), 482-491, 2010	795	2010
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer P Laurent-Puig, A Cayre, G Manceau, E Buc, JB Bachet, T Lecomte, ... Journal of clinical oncology 27 (35), 5924-5930, 2009	793	2009
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma EOF Research, TO Cancer, ... Journal of hepatology 56 (4), 908-943, 2012	770	2012
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus … U Vanhoefer, P Rougier, H Wilke, MP Ducreux, AJ Lacave, E Van Cutsem, ... Journal of Clinical Oncology 18 (14), 2648-2657, 2000	691	2000
Patients with initially unresectable colorectal liver metastases: is there a possibility of cure R Adam, DA Wicherts, RJ de Haas, O Ciacio, F Lévi, B Paule, M Ducreux, ... J Clin Oncol 27 (11), 1829-1835, 2009	589	2009
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy D Elias, F Blot, A El Otmany, S Antoun, P Lasser, V Boige, P Rougier, ... Cancer 92 (1), 71-76, 2001	514	2001
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year T de Baere, D Elias, C Dromain, MGE Din, V Kuoch, M Ducreux, V Boige, ... American Journal of Roentgenology 175 (6), 1619-1625, 2000	509	2000
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial G Pelletier, M Ducreux, F Gay, M Luboinski, H Hagège, D Thong, ... Journal of hepatology 29 (1), 129-134, 1998	498	1998
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin E Mitry, E Baudin, M Ducreux, JC Sabourin, P Rufie, T Aparicio, P Lasser, ... British Journal of Cancer 81 (8), 1351-1355, 1999	497	1999
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma D Elias, T De Baere, A Roche, M Ducreux, J Leclere, P Lasser Journal of British Surgery 86 (6), 784-788, 1999	410	1999

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir a este autor

Citado por

Coautores